>
NervGen Pharma logo

NGEN - NervGen Pharma Share Price

C$2.5 0.0  1.2%

Last Trade - 19/10/21

Sector
Healthcare
Size
Small Cap
Market Cap £60.0m
Enterprise Value £55.7m
Revenue £n/a
Position in Universe 841st / 2701
Bullish
Bearish
Unlock NGEN Revenue
Momentum
Relative Strength (%)
1m +9.11%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.42%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, NervGenPharma Corp revenues was not reported. Net loss increased11% to C$5M. Higher net loss reflects Clinical increasefrom C$230K to C$482K (expense), Pre-clinical increase of80% to C$499K (expense), Other research and developmentincrease from C$24K to C$164K (expense). Basic Earnings perShare excluding Extraordinary Items remained flat at-C$0.14.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NGEN Revenue Unlock NGEN Revenue

Net Income

NGEN Net Income Unlock NGEN Revenue

Normalised EPS

NGEN Normalised EPS Unlock NGEN Revenue

PE Ratio Range

NGEN PE Ratio Range Unlock NGEN Revenue

Dividend Yield Range

NGEN Dividend Yield Range Unlock NGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NGEN EPS Forecasts Unlock NGEN Revenue
Profile Summary

NervGen Pharma Corp. is a Canada-based biotechnology company. The Company is focused on developing solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is also developing drugs for the treatment of spinal cord injury (SCI), multiple sclerosis (MS) and Alzheimer’s disease. Its platform technology targets protein tyrosine phosphatase sigma (PTP sigma), a neural receptor that impedes nerve repair. The PTP sigma receptor promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. The Company’s lead product is NVG-291 referred to intracellular signaling peptide (ISP), treatment for SCI and MS.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated January 19, 2017
Public Since March 13, 2019
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange TSX Venture Exchange
Shares in Issue 41,106,874
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NGEN
Upcoming Events for NGEN
Frequently Asked Questions for NervGen Pharma
What is the NervGen Pharma share price?

As of 19/10/21, shares in NervGen Pharma are trading at C$2.5, giving the company a market capitalisation of £60.0m. This share price information is delayed by 15 minutes.

How has the NervGen Pharma share price performed this year?

Shares in NervGen Pharma are currently trading at C$2.5 and the price has moved by 49.7% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the NervGen Pharma price has moved by 16.41% over the past year.

What are the analyst and broker recommendations for NervGen Pharma?

There are no analysts currently covering NervGen Pharma.

When will NervGen Pharma next release its financial results?

NervGen Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the NervGen Pharma dividend yield?

NervGen Pharma does not currently pay a dividend.

Does NervGen Pharma pay a dividend?

NervGen Pharma does not currently pay a dividend.

When does NervGen Pharma next pay dividends?

NervGen Pharma does not currently pay a dividend.

How do I buy NervGen Pharma shares?

To buy shares in NervGen Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of NervGen Pharma?

Shares in NervGen Pharma are currently trading at C$2.5, giving the company a market capitalisation of £60.0m.

Where are NervGen Pharma shares listed? Where are NervGen Pharma shares listed?

Here are the trading details for NervGen Pharma:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: NGEN
What kind of share is NervGen Pharma?

Based on an overall assessment of its quality, value and momentum, NervGen Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a NervGen Pharma share price forecast 2021?

Shares in NervGen Pharma are currently priced at C$2.5. At that level they are trading at 0.126% discount to the analyst consensus target price of 0.00.

Analysts covering NervGen Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.28 for the next financial year.

How can I tell whether the NervGen Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NervGen Pharma. Over the past six months, the relative strength of its shares against the market has been 48.75%. At the current price of C$2.5, shares in NervGen Pharma are trading at 29.74% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the NervGen Pharma PE Ratio?

We were not able to find PE ratio data for NervGen Pharma.

Who are the key directors of NervGen Pharma?

NervGen Pharma's management team is headed by:

William Radvak - CHM
Michael Abrams - IND
Brian Bayley - IND
Harold Punnett - IND
Paul Brennan - PRE
Amy Franke - VOP
Who are the major shareholders of NervGen Pharma?

Here are the top five shareholders of NervGen Pharma based on the size of their shareholding:

Punnett, Harold Individual Investor
Percentage owned: 5.72% (2.35m shares)
Radvak (William J) Individual Investor
Percentage owned: 3.26% (1.34m shares)
Brennan (Paul Anthony) Individual Investor
Percentage owned: 1.39% (569k shares)
Bayley (Brian E) Individual Investor
Percentage owned: 0.85% (350k shares)
FNY Investment Advisers LLC Investment Advisor/Hedge Fund
Percentage owned: 0.02% (6.50k shares)
Similar to NGEN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.